New drugs for the treatment of attention-deficit/hyperactivity disorder

Expert Opinion on Emerging Drugs

Volumn 9, Issue 2, 2004, Pages 293-302

  Pataki, Caroly S ^b   Feinberg, David T ^a   McGough, James J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amphetamine; Atomoxetine; Attention deficit hyperactivity disorder; Methylphenidate; Pharmacotherapy

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; AMPHETAMINIL; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ATOMOXETINE; CENTRAL STIMULANT AGENT; CLONIDINE; DEXAMPHETAMINE; DEXEDRINE SPANSULE; DEXMETHYLPHENIDATE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE UPTAKE INHIBITOR; GLUTAMATE RECEPTOR AGONIST; GUANFACINE; HISTAMINERGIC RECEPTOR AFFECTING AGENT; LONG ACTING DRUG; METHYLIN ER; METHYLPHENIDATE; MODAFINIL; NICOTINIC AGENT; NORADRENALIN UPTAKE INHIBITOR; NS 2359; PEMOLINE; SPD 465; SPD 473; SPD 483; SPD 503; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ACADEMIC ACHIEVEMENT; ANAMNESIS; ANOREXIA; ATTENTION DEFICIT DISORDER; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DIZZINESS; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; GASTROINTESTINAL SYMPTOM; GENETIC SUSCEPTIBILITY; HEADACHE; HEART MUSCLE CONDUCTION DISTURBANCE; HERITABILITY; HUMAN; LIVER FAILURE; MENTAL INSTABILITY; META ANALYSIS; MOTOR DYSFUNCTION; NERVOUSNESS; NORADRENERGIC SYSTEM; OCCUPATIONAL HEALTH; OUTCOMES RESEARCH; PARENT; PATHOPHYSIOLOGY; PRESCRIPTION; PSYCHOSOCIAL CARE; REBOUND; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOCIAL ADAPTATION; SOCIAL DISABILITY; SOCIAL INTERACTION; STOMACH PAIN; SUSTAINED RELEASE PREPARATION; SYSTEMATIC REVIEW; TRAINING; URINE RETENTION; VOMITING; WEIGHT REDUCTION;

AMPHETAMINES; ANTIDEPRESSIVE AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; METHYLPHENIDATE; PROPYLAMINES;

EID: 10344222923     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.9.2.293     Document Type: Review

References (80)

1. SZATMARI P, OFFORD DR, BOYLE MH: Ontario child health study: prevalence of attention deficit disorder with hyperactivity. J. Child Psychol. Psychiatry (1989) 30:219-230.
2. KANBAYASHI Y, NAKATA Y, FUJII K, KITA M, WADA K: ADHD-related behavior among non-referred children: parents' ratings of DSM-III-R symptoms. Child Psychiatry Hum. Dev. (1994) 25:13-29.
3. BAUMGAERTAL A, WOLRAICH M, DIETRECH M: Comparison of diagnostic criteria for attention deficit hyperactivity disorder in a German elementary school sample. J. Am. Acad. Child Adolesc. Psychiatry (1995) 34:629-638.
4. JENSEN PS, WATANABE HK, RICHTERS JE, CORTES R, ROPER M, LIU S: Prevalence of mental disorder in military children and adolescents: findings from a two-stage community survey. J. Am. Acad. Child Adolesc. Psychiatry (1995) 34:1514-1524.
5. WOLRAICH ML, HANNAH JN, PINNOCK TY, BAUMGAERTAL A, BROWN J: Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J. Am. Acad. Child Adolesc. Psychiatry (1996) 35:319-324.
6. SZATMARI P: The epidemiology of attention-deficit hyperactivity disorders. In Child and Adolescent Psychiatry Clinics of North America: Attention deficit disorder. G Weiss (Ed.), Saunders, Philadelphia (1992).
7. LAUFER MW, DENHOFF E: Hyperkinetic behavior syndrome in children. J. Pediatr. (1957) 50:463-474.
8. WILENS TE, BIEDERMAN J, SPENCER TJ: Attention deficit/hyperactivity disorder across the lifespan. Annu. Rev. Med. (2002) 53:113-131. Excellent review article of ADHD phenomenology and treatment.
9. MURPHY K, BARKLEY RA: Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Comp. Psychiatry (1996) 37:393-401.
10. MURPHY K, BARKLEY RA: Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers; implications for clinical diagnosis. J. Att. Disorders (1996) 1:147-161.
11. BARKLEY RA, FISCHER M, SMALLISH L, FLETCHER K: The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J. Abnorm. Psychol. (2002) 111:279-289. Longitudinal ADHD follow-up study demonstrating rate of persistence into young adulthood.
12. th Annual Meeting of the American Psychiatric Association. New York (2004).
13. BARKLEY RA: Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J. Clin. Psychiatry (2002) 63(Suppl. 12):10-15.
14. ROBISON LM, SCLAR DA, GALIN RS: National trends in the prevalence of attention - deficit disorder and the prescribing of methylphenidate among school-age children: 1990-1995. Clin. Pediatr. (1999) 38:209-217.
15. CHAN E, ZHAN C, HOMER CJ: Health care use and costs for children with attention deficit/hyperactivity disorder, national estimates from the medical expenditure panel survey. Arch. Pediatr. Adolesc. Med. (2002) 156:504-511.
16. BIEDERMAN J, WILENS TE, MICK E, FARAONE SV, SPENCER T: Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol. Psychiatry (1998) 44:269-273.
17. WILENS TE, BIEDERMAN J, MICK E: Does ADHD effect the course of substance abuse? Findings from a sample of adults with and without ADHD. Am. J. Addict. (1998) 7:156-163.
18. POMERLEAU CS, DOWNEY KK, SNEDECKOR SM, MEHRINGER AM, MARKS JL, POMERLEAU OF: Smoking patterns and abstinence effects in smokers with no ADHD, childhood ADHD, and adult ADHD symptomatology. Addict. Behav. (2003) 28:1149-1157.
19. BIEDERMAN J, FARAONE SV, SPENCERT et al.: Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am. J. Psychiatry (1993) 150:1792-1798.
20. MANNUZZA S, KLEIN RG, BESSLER A, MALLOY P, LAPADULA M: Adult outcome of hyperactive boys. Am. J. Psychiatry (1993) 50:565-576.
21. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition-Text Revision (DSM-IV-TR). Washington, D.C., American Psychiatric Association (2000).
22. FARAONE SV, DOYLE AE: The nature and heritability of attention-deficit/ hyperactivity disorder. Child Adolesc. Psychiatr. Clin. N. Am. (2001) 10:299-316.
23. ARCOS-BURGOS M, CASTELLANOS FX, KONECKI D et al.: Pedigree disequilibrium test (PDT) replicates association and linkage between DRD4 and ADHD in multigenerational and extended pedigrees from a genetic isolate. Mol. Psychiatry (2004) 9:252-259.
24. BAKKER SC, VAN DER MEULEN EM, BUITELAAR JK et al.: A whole-genome scan in 164 Dutch sib pairs with attention-deficit/hyperactivity disorder; suggestive - evidence for linkage on chromosomes 7p and 15q. Am. J. Hum. Genet. (2003) 72:1251-1260.
25. FISCHER SE, FRANKS C, MCCRACKEN JT et al.: A genome-wide scan for loci involved in attention-deficit/hyperactivity disorder (ADHD). Am. J. Hum. Genet. (2002) 70:1183-1196. First ADHD genome scan.
26. COOK EH, STEIN MA, KRASOWSKI MD et al.: Association of attention deficit disorder and the dopamine transporter gene. Am. J. Hum. Genet. (1995) 56:993-998.
27. FARAONE SV, DOYLE AE, MICK E, BIEDERMAN J: Meta-analysis of the association between the 7-repeat allele of the dopamine d(4) receptor gene and attention deficit hyperactivity disorder. Am. J. Psychiatry (2001) 158:104-113.
28. MAHER BS, MARAZITA ML, FERRELL RE, VANYUKOV MM: Dopamine system genes and attention deficit hyperactivity disorder; a meta-analysis. Psychiatr. Genet. (2002) 12:207-215.
29. SMALLEY SL: Genetic influences in childhood-onset psychiatric disorders: autism and attention-deficit/hyperactivity disorder. Am. J. Hum. Genet. (1997) 60:1276-1282.
30. MICK E, BIEDERMAN J, FARAONE SV, SAYER J, KLEINMAN NS: Case-control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol us, and drug use during pregnancy. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41:378-385.
31. MILBERGER S, BIEDERMAN J, FARAONE SV, CHEN L, JONES J: Is maternal smoking a risk factor for attention deficit hyperactivity disorder in children. Am. J. Psychiatry (1996) 153:1138-1142.
32. KOTIMAA AJ, MIOLANEN I, TAANILA A et al.: Maternal smoking and hyperactivity in 8-year old children. J. Am. Acad. Child Adolesc. Psychiatry (2003) 42:826-833.
33. TUTHILL RW: Hair lead levels related to children's classroom attention-deficit behavior. Arch. Environ. Health (1996) 51:363-383.
34. LEIBSON CL, KATUSIC SK, BARBARESI WJ, RANSOM J, O'BRIEN PC: Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA (2001) 285:60-66.
35. GUEVARA J, LOZANO P, WICKIZER T, MELL L, GEPHART H: Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics (2001) 108:71-78.
36. SZATMARI P, OFFORD DR, BOYLE MH: Correlates, associated impairments and patterns of service utilization of children with attention deficit disorder. J. Child Psychol. Psychiatry (1989) 30:205-217.
37. BARKLEY RA, MURPHY KR, KWASNIK D: Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics (1996) 98:1089-1095.
38. BARKLEY RA, FISCHER M, SMALLISH L, FLETCHER K: Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics (2003) 112:1459-1460. Longitudinal study showing no increased risk of substance abuse in children treated with stimulants.
39. WILENS TE, FARAONE SV, BIEDERMAN J, GUNAWARDENE S: Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics (2003) 111:179-185.
40. GREENHILL LL, HALPERIN JM, ABIKOFF H: Stimulant medications. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38:503-512.
41. SAYLOR KE, BUERMEYER CM, SPENCER TJ, BARKLEY RA: Adaptive changes related to medication treatment of ADHD: listening to parents of children in clinical trials of a novel nonstimulant medication. J. Clin. Psychiatry (2002) 63(Suppl. 12):23-28.
42. SPENCER T, BIEDERMAN J, WlLENS T et al.: Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J. Am. Acad. Child Adolesc. Psychiatry (1996) 35:409-432.
43. ELIA J, BORDCHERDING B, RAPOPORT J, KEYSOR C: Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res. (1991) 36:141-155.
44. BARKLEY RA, MCMURRAY MG, EDELBROCK CS et al: Side effects of methylphenidate in children with attention deficit hyperactivity disorder; a systematic, placebo-controlled evaluation. Pediatrics (1990) 86:184-192.
45. BIEDERMAN J, LOPEZ FA, BOELLNER SW, CHANDLER MC: A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics (2002) 110:258-266.
46. th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Honolulu, HI (2001).
47. WILENS T, PELHAM W, STEIN M et al.: ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J. Am. Acad. Child Adolesc. Psychiatry (2003) 42:424-433.
48. MCGOUGH JJ, BIEDERMAN J, WIGAL S et al.: Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J. Am. Acad. Child Adolesc. Psychiatry (In press).
49. SWANSON JM, KRAEMER HC, HINSHAW SP et al.: Clinical relevance of the primary findings of the MTA; success rates based on severity of ADHD and ODD symptoms at the end of treatment. J. Am. Acad. Child Adolesc. Psychiatry (2001) 40:168-179.
50. th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Miami, FL (2003).
51. CHARACH A, ICKOWICZ A, SCHACHAR R: Stimulant treatment over five years: adherence, effectiveness, and adverse events. J. Am. Acad. Child Adolesc. Psychiatry (2004) 43:559-567. Illustrates problems of adherence with currently available ADHD medications.
52. MICHELSON D, ALLEN AJ, BUSNER J et al.: Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am. J. Psychiatry (2002) 159:1896-1901.
53. MICHELSON D, BUITELAAR JK, DANCKAERTS M et al.: Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J. Am. Acad. Child Adolesc. Psychiatry (2004) 43:896-904.
54. MICHELSON D, ADLER L, SPENCERT et al.: Atomoxetine in adults with ADHD; two randomized, placebo-controlled studies. Biol. Psychiatry (2003) 15:112-120.
55. WERNICKE JF, KRATOCHVIL CJ: Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J. Clin. Psychiatry (2002) 63(Suppl. 12):50-55.
56. WERNICKE JF, ADLER L, SPENCER T et al.: Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J. Clin. Psychopharmacol. (2004) 24:30-35.
57. th Meeting of the American Psychiatric Association. New York (2004).
58. th Meeting of the American Psychiatric Association. New York (2004).
59. WILENS TE, SPENCER TJ, BIEDERMAN J et al.: A controlled clinical trial of buproprion for attention-deficit/hyperactivity disorder in adults. Am. J. Psychiatry (2001) 158:282-288.
60. BARRICKMAN LL, PERRY PJ, ALLEN AJ et al.: Buproprion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry (1995) 34:649-657.
61. th Annual Meeting. NCDEU, Phoenix (2004).
62. HEDGES D, REIMHERR FW, ROGERS A, STRON R, WENDER PH: An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol. Bull. (1995) 31:779-783.
63. FINDLING RL, SCHWARTZ MA, FLANNERY DJ, MANOS MJ: Venlafaxine in adults with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38:1551-1559.
64. WILENS TE, BIEDERMAN J, PRINCE J et al.: Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am. J. Psychiatry. (1996) 153:1147-1153.
65. SPENCER T, BIEDERMAN J, COFFEY B: A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry (2002) 59:649-656.
66. PATAKI CS, CARLSON GA, KELLY KL et al.: Side effects of methylphenidate and desipramine alone and in combination in children. J. Am. Acad. Child Adolesc. Psychiatry (1993) 32:1065-1072.
67. JENSEN P, KETTLE L, ROPER MT et al.: Are stimulants overprescribed? Treatment of ADHD in four U.S. communities. Am. Acad. Child Adolesc. Psychiatry (1999) 38:269-270. Epidemiological study demonstrating that rates of ADHD treatment are less than the estimated prevalence of the disorder.
68. SPENCER TJ, BIEDERMAN J, WILENS TE, FARAONE SV: Overview and neurobiology of attention-deficit/ hyperactivity disorder. J. Clin. Psychiatry (2002) 63(Suppl. 12):3-9.
69. PLISZKA SR, MCCRACKEN JT, MAAS JW: Catecholamines in attention-deficit hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry (2002) 35:264-272.
70. SOLANTO MV: Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav. Brain Res. (2002) 130:65-71.
71. DOUGHERTY DD, BONAB AA, SPENCER TJ et al.: Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet (1999) 354:2132-2133.
72. KRAUSEK H, DRESEL SH, DRASUSE J, KUNG HF, TATSCH K: Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci. Lett. (2000) 285:107-110.
73. WINSBURG BG, COMINGS DE: Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38:1474-1477.
74. ROMAN T, SZOBOT C, MARTINE S, BIEDERMAN J, ROHDE LA, HUTZ MH: Dopamine transporter gene and response to methylphenidate in attention-deficit/ hyperactivity disorder. Pharmacogenetics (2002) 12:497-499.
75. KIRLEY A, LOWE N, HAWI A et al: Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am. J. Med. Genetics (2003) 121:B50-B54.
76. STEIN MA, WALDMAN ID, SARAMPOTE C, SEYMOUR K, COOK EH: Dopamine transporter genotype (DAT1) predicts stimulant response in children with attention deficit hyperactivity disorder. Pediatric Res. (2004) (In Press).
77. SWANSON JM, WIGAL SB, WIGAL T et al.: A comparison of once-daily extended release methylphenidate formulations in children with attention-deficit/ hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics (2004) 113:E206-E216.
78. PLISZKA SR, BROWNE RG, OLVERA RL, WYNNE SK: A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry (2000) 39:619-626.
79. AUILER JF, LIU K, LYNCH JM, GELOTTE CK: Effects of food on early drug exposure from extended-release stimulants; results from the Concerta, Adderall XR Food Evaluation (CAFÉ) Study. Curr. Med. Res. Opin. (2002) 18:311-316.
80. http://www.iddb3.com The Investigational Drugs Database © 1997-2004 Derwent Information Ltd.